• Indian Indices
  • Global Indices
  • Commodities
  • Currency
Sensex
  • Sensex
  • Nifty
{{x.close_price| number:2}} {{x.netchg| number:2}} ({{x.perchg | number:2}}%)
Open - {{x.open | number:2}}
Prev Close - {{x.prevclose|number:2}}
Today's High - {{x.high|number:2}}
Today's Low - {{x.low|number:2}}
Advances/Declines (30 Companies)
  • 1D
  • 1W
  • 1M
  • 1Yr
  • 5Yr
{{x.upd_time}}
FTSE 100
  • FTSE 100
  • DJIA
  • NIKKEI 225
  • HANG SENG
{{x.Date}}
{{x.close| number:2}} {{x.Chg | number:2}} ({{x.PChg | number:2}}%)
Open - {{x.close | number:2}}
Prev Close - {{x.PrevClose|number:2}}
Gold
  • Gold
  • Silver
  • Crude Oil
  • Copper
{{x.Trd_Date}} ( {{x.Time}} )
{{x.ClosePrice| number:2}} {{x.change| number:2}} ({{x.perchange | number:2}}%)
Exchange - MCX
Open - {{x.Open|number:2}}
Exp Date - {{x.Exp_Date}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevClose|number:2}}
Today's Low - {{x.Low|number:2}}
USDINR
  • USDINR
  • GBPINR
  • EURINR
  • JPYINR
{{x.Lasttrdtime}} ( {{x.Time}} )
{{x.ltp| number:2}} {{x.PriceDiff| number:2}} ({{x.PerChange | number:2}}%)
Exchange - NSE
Open - {{x.Open|number:2}}
Exp Date - {{x.Expirydate}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevPrice|number:2}}
Today's Low - {{x.Low|number:2}}
As On 05-Aug-2021 EOD, Market Closed
SENSEX
54,492.84
123.07 (0.23%)
NIFTY
16,294.60
35.80 (0.22%)
    No Companies Visited

Back to news list
  • Gland Pharma hits record high after Q1 PAT spurts 12% YoY to Rs 351 cr

    Gland Pharma rose 1.92% to Rs 3,875.15 after the company's net profit jumped 11.81% to Rs 350.65 crore on 30.50% increase in revenue from operations to Rs 1,153.90 crore in Q1 June 2021 (Q1 FY22) over Q1 June 2020 (Q1 FY21).

    The growth in revenue was contributed from a mix of launch of new products and volume growth in existing products. The key markets, US, Canada, Europe and Australia registered a growth of 16% and accounted for 61% of the revenue during Q1 FY22. This performance is driven by growth of key products like Micafungin, Enoxaparin, Heparin, Dexmedetomidine and new product launches.

    Profit before tax surged 12.34% to Rs 471.84 crore in Q1 FY22 as against Rs 420 crore in Q1 FY21. The Q1 earnings was declared on Wednesday, 21 July 2021. The markets were closed on Wednesday on account of Eid al-Adha.

    EBITDA grew 12% to Rs 498.10 crore in Q1 FY22 as against Rs 444.70 crore in Q1 FY21. EBITDA margin stood at 41% during the quarter as compared to 49% during Q1 June 2020. Profit margin was at 29% in Q1 June 2021 compared with 34% during Q1 June 2020.

    During the quarter, several new launches have contributed to the growth and it was an important milestone to launch first set of penem products for the US market. The 'Rest of the World' markets have seen a robust growth of 51% in line with the increased focus on geographic expansion. This is driven by increased penetration by forming new partnerships in various countries.

    India accounted for 20% of Q1 FY22 revenue and witnessed a 77% Y-o-Y (year-on-year) growth for the quarter. Gland Pharma ramped up supply of essential drugs like Remdesivir and Enoxaparin to support the domestic market requirement during the second wave of COVID-19.

    The total Research and Development (R&D) expense for first quarter of the FY 2022 was at Rs 43.80 crore, which was 3.8% of revenue and registered an increase of 74% over the first quarter of previous financial year. During the quarter ended 30 June 2021, Gland Pharma filed 2 Abbreviated New Drug Applications (ANDAs), 5 Drug Master Files (DMFs) and received 6 ANDA approvals.

    As on 30 June 2021, the company along with its partners have filed total 286 ANDAs, out of which 239 were approved and 47 are pending approval. The total capex incurred during the quarter ended was 30 June 2021 was at Rs 185.70 crore.

    Commenting on the Q1 results, Srinivas Sadu, managing director (MD) and chief executive officer (CEO) of Gland Pharma, said: "In spite of the challenges from the second wave of COVID-19 in the country, in terms of manpower availability and supply chain bottlenecks, Gland Pharma has managed to deliver strong quarterly results. The revenue for the quarter stood at Rs 11,539 million, which is a Y-o-Y revenue growth of 31%, with a PAT margin of 29%, which is Rs 3,507 million."

    "Our execution capabilities, be it uninterrupted commercial supplies, project commissioning or new product launches, is what underpins our strong performance in this quarter. It was an important milestone for the company to launch our first set of Penem products for the US market during the quarter. The dedicated suite for vaccine drug product fill finish is now ready for vaccine commercial production, while the tech transfer for the drug substance manufacturing is ongoing. We continue to support the nation by ramping up production of essential COVID drugs."

    Hyderabad-based Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. It operates primarily under a business to business (B2B) model and it engaged in development, manufacturing and marketing of complex injectables.

    The scrip hit a record high at Rs 4,000 during intraday trade.

    Back to news list
Previous Stories :
More
Hot Pursuit News

Quick Links

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Capital Market Publishers India Pvt. Ltd.

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071.
91-22-25229720
91-22-25230011
Kindly note www.capitalmarket.com does not send any mobile SMS, whatsapp or twitter messages
giving any kind of stock recommendations.
For Capital Market Magazine queries mail to : subscription@capitalmarket.com
For Capital Market Online Products related queries mail to : financeshop@capitalmarket.com
For any other Capital Market Website related Queries mail to : info@capitalmarket.com
To advertise on Capital Market Websites & Capital Market Fortnightly magazine mail to : advt@capitalmarket.com
Flash News 05-Aug-2021
  •  ( 15:59) REC Q1 FY22 PAT up 22.16% Y-o-Y to Rs 2,246.60 cr  
  •  ( 15:12) GAIL (India) consol. Q1 FY22 PAT up 235.49% Y-o-Y to Rs 2,157.15 cr  
  •  ( 15:10) Escorts Q1 PAT up nearly 93% YoY to Rs 178.5 crore  
  •  ( 13:41) European markets advance on Aug. 5 as investors digest corporate earnings  
  •  ( 13:40) Benchmarks attain all-time high again; The Nifty index reach 16,300 level  
  •  ( 12:42) The Nifty PSU Bank index snaps 3-day gaining trend  
  •  ( 12:41) The Nifty index traded above 16,250 level; weak market breadth  
  •  ( 12:40) Indices yield small returns after bouncing out of negative territory  
  •  ( 11:58) Life Insurance Corporation of India acquires 0.029% stake of JSW Steel  
  •  ( 11:54) Life Insurance Corporation of India acquires 0.029% stake of JSW Steel on Aug. 3  
  •  ( 11:21) Jindal Steel & Power July 2021 steel sales rise 5% Y-o-Y to 6.7 lakh tonnes  
  •  ( 10:05) Apollo Tyres consol. Q1 FY22 PAT stands at Rs 127.79 cr  
  •  ( 09:30) Adani Total Gas consol. Q1 FY22 PAT up 266.43% Y-o-Y to Rs 142.58 cr  
  •  ( 09:29) Sensex, Nifty retreat after scaling record high; breadth weak   
  •  ( 09:29) Kumar Mangalam Birla to step down as Vodafone Idea chairman  
  •  ( 08:22) US services sector index races to record high in July -ISM survey  
  •  ( 08:20) Asia-Pacific stocks trading mixed  
Show News
05 August 2021 00:00
2989.00
(-0.90 %)
749.15
(-0.59 %)
3818.70
(-0.35 %)
6247.85
(-1.78 %)
13994.15
(-1.36 %)
598.90
(4.30 %)
4783.30
(0.25 %)
2660.80
(-0.56 %)
1060.80
(1.93 %)
1485.65
(1.42 %)
2358.80
(-0.76 %)
702.10
(-1.77 %)
998.15
(-2.13 %)
1654.85
(0.35 %)
215.15
(3.14 %)
1772.70
(1.31 %)
1626.65
(0.25 %)
759.15
(-0.89 %)
7026.50
(-1.06 %)
18214.25
(0.91 %)
116.50
(-0.98 %)
175.00
(-0.09 %)
2133.30
(1.41 %)
441.85
(-3.33 %)
785.85
(0.03 %)
1446.40
(2.15 %)
3285.15
(0.36 %)
1247.85
(2.55 %)
1799.05
(-0.04 %)
7657.55
(-1.20 %)
Sensex 5min and Nifty 15min delayed as on .
Show Ticker
Rotate your device

Rotate your device

For the best experience please go back to portrait mode.